Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end conventional diet and exercise programs.
Published data in a prominent medical journal points out that while obese people can lose about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying such medications must be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery means a return to pre-treatment weight in about a year and a half.
Comparing Treatments
The research, which examined 37 of studies involving over 9,000 of participants, compared the results of the injectable medications with other pills.
Researchers emphasize that individuals who lose weight through lifestyle changes alone typically see a slower creep back—around 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors believe the mechanism of the injections is key to understanding the accelerated rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal may cause the system to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is unsuppressed, making overeating far more likely."
A Lifelong Issue?
The NHS suggest the jabs for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, given the significant potential of weight regain, the treatment should be considered ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent character of obesity," similar to managing conditions like diabetes.
User Accounts
Users who have come off the jabs describe a powerful resurgence of appetite.
"It was like a trigger activating and you become starving," said an individual.
This challenge is exacerbated if individuals have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Interest
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while these medications are effective agents for weight loss, they are not a magic fix and long-term success relies on combined behavioural support.
